CYP2C19 and Alzheimer disease: Compared with a standard power of 0.8, the calculated power range for the associations between CYP2C19 metabolizer status and switching/discontinuing AD treatment was 0.06–0.13, while this was 0.27–0.29 for CYP2D6 metabolizer status.